[Studies on the usefulness of a long-term, high-dose treatment of methylcobalamin in patients with oligozoospermia].

Abstract

Methylcobalamin (CH3-B12) was administrated in a dose of 6 mg per day (group A, 16 cases) or 12 mg per day (group B, 23 cases) for 16 weeks to patients with oligozoospermia. There was no difference between group A and group B regarding vitamin B12 concentrations in the serum or seminal fluid. CH3-B12 appeared to be transported to seminal fluid very efficiently. However, results from group A and group B did not differ with respect to this parameter. The efficacy rate for group A was 37.5% and that for group B was 39.1%. From these results, it was concluded that a long-term, high dose treatment of CH3-B12 was useful for the treatment of patients with oligozoospermia. Since the efficacy rates were not different between the two groups, 6 mg per day would be the recommended dose. Clinical adverse reactions were observed in one patient in each group. Drug-related laboratory adverse reactions were observed in only one patient in group B.

• Authors: H Moriyama, K Nakamura, N Sanda, E Fujiwara, S Seko, A Yamazaki, M Mizutani, K Sagami, T Kitano
• Journal: Hinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 33 Issue 1 Pg. 151-6 (Jan 1987) ISSN: 0018-1994 [Print] Japan
• PMID: 3107356 (Publication Type: English Abstract, Journal Article)

Chemical References

• Luteinizing Hormone
• Follicle Stimulating Hormone
• mecobalamin
• Vitamin B 12

Topics

• Adult
• Follicle Stimulating Hormone (blood)
• Humans
• Luteinizing Hormone (blood)
• Male
• Oligospermia (blood, drug therapy)
• Sperm Count
• Vitamin B 12 (administration & dosage, analogs & derivatives, blood, therapeutic use)